Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematologic Neoplasms | 31 | 2024 | 1907 | 6.170 |
Why?
|
Myelodysplastic Syndromes | 23 | 2023 | 1399 | 4.990 |
Why?
|
Terminal Care | 12 | 2023 | 1770 | 2.080 |
Why?
|
Neoplasms | 30 | 2024 | 22371 | 1.940 |
Why?
|
Geriatric Assessment | 12 | 2024 | 1422 | 1.830 |
Why?
|
Cancer Care Facilities | 6 | 2024 | 427 | 1.610 |
Why?
|
Hospice Care | 10 | 2023 | 678 | 1.610 |
Why?
|
Anemia | 5 | 2023 | 1514 | 1.390 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 11 | 2023 | 1437 | 1.350 |
Why?
|
Leukemia, Myeloid, Acute | 13 | 2024 | 3626 | 1.350 |
Why?
|
Hematopoietic Stem Cell Transplantation | 13 | 2024 | 5717 | 1.300 |
Why?
|
Health Care Rationing | 3 | 2021 | 435 | 1.270 |
Why?
|
Ethics Consultation | 3 | 2024 | 59 | 1.240 |
Why?
|
Leukemia | 3 | 2024 | 1519 | 1.080 |
Why?
|
Antineoplastic Agents | 18 | 2024 | 13676 | 1.070 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2024 | 300 | 1.050 |
Why?
|
Bone Marrow Examination | 3 | 2016 | 154 | 1.000 |
Why?
|
Quality of Life | 22 | 2024 | 13490 | 0.990 |
Why?
|
Myelodysplastic-Myeloproliferative Diseases | 1 | 2023 | 15 | 0.880 |
Why?
|
Medical Oncology | 10 | 2023 | 2346 | 0.860 |
Why?
|
Bone Marrow Cells | 3 | 2016 | 2414 | 0.820 |
Why?
|
Marketing of Health Services | 2 | 2014 | 151 | 0.730 |
Why?
|
Aged | 73 | 2024 | 171504 | 0.700 |
Why?
|
Multiple Myeloma | 8 | 2023 | 5196 | 0.690 |
Why?
|
Artificial Intelligence | 3 | 2024 | 2665 | 0.680 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 879 | 0.680 |
Why?
|
Humans | 145 | 2024 | 768166 | 0.670 |
Why?
|
Empathy | 1 | 2024 | 474 | 0.670 |
Why?
|
Quality of Health Care | 5 | 2018 | 4310 | 0.640 |
Why?
|
Specimen Handling | 2 | 2014 | 708 | 0.630 |
Why?
|
Blood Transfusion | 3 | 2020 | 1309 | 0.620 |
Why?
|
Resource Allocation | 1 | 2021 | 354 | 0.620 |
Why?
|
Hepatitis B | 1 | 2024 | 711 | 0.610 |
Why?
|
Internet | 2 | 2024 | 3110 | 0.610 |
Why?
|
Awareness | 2 | 2015 | 654 | 0.610 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 5 | 2014 | 696 | 0.590 |
Why?
|
State Government | 1 | 2021 | 388 | 0.580 |
Why?
|
Hematology | 5 | 2020 | 243 | 0.570 |
Why?
|
Aged, 80 and over | 37 | 2024 | 59629 | 0.570 |
Why?
|
Hematinics | 3 | 2016 | 282 | 0.550 |
Why?
|
Salaries and Fringe Benefits | 1 | 2019 | 263 | 0.540 |
Why?
|
Standard of Care | 1 | 2021 | 568 | 0.530 |
Why?
|
Erythrocyte Transfusion | 1 | 2021 | 575 | 0.520 |
Why?
|
Hemoglobins | 2 | 2020 | 1531 | 0.520 |
Why?
|
Radiation Oncology | 1 | 2022 | 572 | 0.520 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2015 | 240 | 0.520 |
Why?
|
Disease Management | 4 | 2020 | 2536 | 0.510 |
Why?
|
Cause of Death | 2 | 2017 | 3721 | 0.510 |
Why?
|
Patient Selection | 4 | 2020 | 4260 | 0.510 |
Why?
|
Drug Industry | 3 | 2016 | 791 | 0.510 |
Why?
|
Clinical Trials as Topic | 4 | 2024 | 8054 | 0.500 |
Why?
|
SEER Program | 7 | 2018 | 1444 | 0.500 |
Why?
|
Drug Substitution | 1 | 2018 | 291 | 0.490 |
Why?
|
Male | 75 | 2024 | 364719 | 0.480 |
Why?
|
Health Services Accessibility | 3 | 2024 | 5520 | 0.470 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7454 | 0.460 |
Why?
|
Search Engine | 1 | 2015 | 142 | 0.450 |
Why?
|
Vincristine | 5 | 2022 | 1040 | 0.450 |
Why?
|
United States | 34 | 2024 | 73039 | 0.450 |
Why?
|
Female | 79 | 2024 | 397192 | 0.450 |
Why?
|
Frail Elderly | 6 | 2023 | 781 | 0.450 |
Why?
|
Hospices | 3 | 2023 | 245 | 0.440 |
Why?
|
Referral and Consultation | 5 | 2022 | 3620 | 0.440 |
Why?
|
Environmental Monitoring | 1 | 2020 | 1469 | 0.430 |
Why?
|
Climate Change | 1 | 2020 | 509 | 0.430 |
Why?
|
Perception | 4 | 2018 | 1209 | 0.420 |
Why?
|
Glucaric Acid | 1 | 2012 | 10 | 0.420 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2018 | 4055 | 0.420 |
Why?
|
Comorbidity | 8 | 2021 | 10590 | 0.420 |
Why?
|
Iron-Dextran Complex | 1 | 2012 | 14 | 0.420 |
Why?
|
Consumer Health Information | 1 | 2015 | 215 | 0.410 |
Why?
|
Drugs, Generic | 1 | 2018 | 455 | 0.410 |
Why?
|
Middle Aged | 55 | 2024 | 223492 | 0.400 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15948 | 0.400 |
Why?
|
Economics, Pharmaceutical | 1 | 2012 | 88 | 0.400 |
Why?
|
Lymphoma | 1 | 2021 | 1898 | 0.390 |
Why?
|
Medicare | 9 | 2023 | 6809 | 0.390 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10399 | 0.370 |
Why?
|
Bone Marrow Transplantation | 1 | 2019 | 2709 | 0.370 |
Why?
|
Ferric Compounds | 1 | 2012 | 376 | 0.350 |
Why?
|
Physician-Patient Relations | 7 | 2024 | 3269 | 0.340 |
Why?
|
Palliative Care | 5 | 2021 | 3643 | 0.340 |
Why?
|
Databases, Factual | 3 | 2016 | 8080 | 0.330 |
Why?
|
Quality Indicators, Health Care | 2 | 2016 | 1805 | 0.330 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 11878 | 0.330 |
Why?
|
Socioeconomic Factors | 5 | 2019 | 7852 | 0.320 |
Why?
|
Patient Preference | 4 | 2019 | 946 | 0.320 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 945 | 0.310 |
Why?
|
Population Surveillance | 3 | 2017 | 2596 | 0.310 |
Why?
|
Aromatase Inhibitors | 1 | 2012 | 519 | 0.310 |
Why?
|
Radiotherapy | 2 | 2017 | 1502 | 0.310 |
Why?
|
Symbolism | 1 | 2008 | 32 | 0.300 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 26379 | 0.300 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2012 | 372 | 0.300 |
Why?
|
Prognosis | 17 | 2023 | 30010 | 0.300 |
Why?
|
Survival Analysis | 8 | 2018 | 10101 | 0.290 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3231 | 0.290 |
Why?
|
Adult | 39 | 2024 | 223646 | 0.280 |
Why?
|
Telemedicine | 1 | 2024 | 3109 | 0.270 |
Why?
|
Lymphoproliferative Disorders | 1 | 2010 | 528 | 0.270 |
Why?
|
Drug Utilization | 1 | 2012 | 1189 | 0.270 |
Why?
|
Delayed Diagnosis | 1 | 2010 | 467 | 0.270 |
Why?
|
Transplantation Conditioning | 1 | 2013 | 1601 | 0.260 |
Why?
|
Health Expenditures | 2 | 2018 | 2389 | 0.260 |
Why?
|
Multivariate Analysis | 6 | 2019 | 12077 | 0.250 |
Why?
|
Physicians, Primary Care | 1 | 2012 | 624 | 0.250 |
Why?
|
Biological Specimen Banks | 2 | 2022 | 788 | 0.240 |
Why?
|
Blood Coagulation Disorders | 1 | 2008 | 350 | 0.240 |
Why?
|
Janus Kinase 2 | 1 | 2008 | 561 | 0.240 |
Why?
|
Risk Assessment | 5 | 2019 | 24315 | 0.240 |
Why?
|
Survival Rate | 9 | 2022 | 12840 | 0.240 |
Why?
|
Greenhouse Effect | 1 | 2024 | 31 | 0.230 |
Why?
|
Information Dissemination | 4 | 2016 | 1143 | 0.230 |
Why?
|
Cognition Disorders | 1 | 2018 | 3980 | 0.230 |
Why?
|
Age Factors | 7 | 2024 | 18412 | 0.220 |
Why?
|
Mastectomy | 2 | 2024 | 1861 | 0.220 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2013 | 1375 | 0.220 |
Why?
|
Positron-Emission Tomography | 3 | 2015 | 6669 | 0.220 |
Why?
|
Bupropion | 1 | 2005 | 303 | 0.220 |
Why?
|
Doxorubicin | 4 | 2014 | 2234 | 0.220 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1668 | 0.210 |
Why?
|
Central Nervous System Neoplasms | 1 | 2011 | 928 | 0.210 |
Why?
|
Massachusetts | 4 | 2024 | 8890 | 0.210 |
Why?
|
Retrospective Studies | 18 | 2024 | 81762 | 0.210 |
Why?
|
Self Report | 4 | 2018 | 3773 | 0.210 |
Why?
|
Molecular Targeted Therapy | 2 | 2016 | 2830 | 0.200 |
Why?
|
Ethics, Clinical | 1 | 2023 | 101 | 0.200 |
Why?
|
Logistic Models | 7 | 2019 | 13290 | 0.200 |
Why?
|
Disease Progression | 3 | 2024 | 13671 | 0.200 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2010 | 1642 | 0.200 |
Why?
|
Employment | 2 | 2019 | 1110 | 0.200 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2005 | 491 | 0.200 |
Why?
|
Bilirubin | 1 | 2024 | 438 | 0.200 |
Why?
|
Prospective Studies | 13 | 2023 | 54926 | 0.190 |
Why?
|
Cohort Studies | 15 | 2016 | 41754 | 0.190 |
Why?
|
Marital Status | 1 | 2023 | 426 | 0.190 |
Why?
|
Health Care Costs | 1 | 2015 | 3239 | 0.190 |
Why?
|
Patients | 3 | 2018 | 908 | 0.190 |
Why?
|
Dioxygenases | 1 | 2024 | 353 | 0.190 |
Why?
|
Insurance, Health | 2 | 2013 | 2517 | 0.190 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 93 | 0.180 |
Why?
|
Treatment Outcome | 16 | 2024 | 65371 | 0.180 |
Why?
|
Electronic Health Records | 1 | 2018 | 4887 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 5 | 2019 | 6526 | 0.180 |
Why?
|
Intensive Care Units | 3 | 2019 | 3800 | 0.180 |
Why?
|
Psychometrics | 3 | 2016 | 3063 | 0.180 |
Why?
|
Prednisone | 3 | 2014 | 1567 | 0.170 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 2 | 2016 | 17 | 0.170 |
Why?
|
Patient Rights | 1 | 2021 | 126 | 0.170 |
Why?
|
Consensus | 2 | 2020 | 3212 | 0.170 |
Why?
|
Mutation | 5 | 2024 | 30238 | 0.170 |
Why?
|
Hospital Bed Capacity | 1 | 2021 | 202 | 0.170 |
Why?
|
Risk Factors | 11 | 2023 | 74944 | 0.170 |
Why?
|
Polypharmacy | 1 | 2022 | 307 | 0.170 |
Why?
|
Thrombosis | 2 | 2016 | 2957 | 0.160 |
Why?
|
Activities of Daily Living | 2 | 2019 | 2430 | 0.160 |
Why?
|
Social Class | 3 | 2018 | 2008 | 0.160 |
Why?
|
Hospitalization | 4 | 2022 | 10840 | 0.160 |
Why?
|
Patient Education as Topic | 1 | 2009 | 2337 | 0.160 |
Why?
|
Cyclophosphamide | 3 | 2014 | 2227 | 0.160 |
Why?
|
Social Justice | 1 | 2024 | 486 | 0.160 |
Why?
|
Pharmacies | 1 | 2021 | 171 | 0.160 |
Why?
|
Lymphoma, Follicular | 2 | 2013 | 460 | 0.160 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2013 | 686 | 0.160 |
Why?
|
Decision Making, Organizational | 1 | 2019 | 136 | 0.160 |
Why?
|
Cytogenetic Analysis | 1 | 2019 | 271 | 0.150 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2024 | 1791 | 0.150 |
Why?
|
United States Food and Drug Administration | 3 | 2016 | 1673 | 0.150 |
Why?
|
Diterpenes | 1 | 2019 | 169 | 0.150 |
Why?
|
Models, Biological | 1 | 2014 | 9495 | 0.150 |
Why?
|
Blood Donors | 1 | 2020 | 343 | 0.150 |
Why?
|
Humanities | 1 | 2018 | 55 | 0.150 |
Why?
|
Prevalence | 3 | 2021 | 15869 | 0.150 |
Why?
|
Proportional Hazards Models | 7 | 2023 | 12543 | 0.150 |
Why?
|
Health Priorities | 1 | 2021 | 380 | 0.150 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 939 | 0.150 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3533 | 0.140 |
Why?
|
Politics | 1 | 2024 | 822 | 0.140 |
Why?
|
Attitude of Health Personnel | 3 | 2021 | 3929 | 0.140 |
Why?
|
Health Care Surveys | 2 | 2017 | 2434 | 0.140 |
Why?
|
HIV Infections | 1 | 2024 | 17569 | 0.140 |
Why?
|
Odds Ratio | 4 | 2019 | 9669 | 0.140 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 373 | 0.140 |
Why?
|
Myeloproliferative Disorders | 1 | 2023 | 616 | 0.140 |
Why?
|
Patient Participation | 1 | 2006 | 1447 | 0.140 |
Why?
|
Off-Label Use | 1 | 2018 | 185 | 0.130 |
Why?
|
Documentation | 1 | 2023 | 917 | 0.130 |
Why?
|
Neoplasm Staging | 5 | 2020 | 11244 | 0.130 |
Why?
|
Transplantation, Autologous | 3 | 2023 | 2120 | 0.130 |
Why?
|
Communication | 3 | 2019 | 3905 | 0.130 |
Why?
|
Leukemia, Myeloid | 1 | 2019 | 693 | 0.130 |
Why?
|
Delphi Technique | 1 | 2020 | 891 | 0.130 |
Why?
|
Hand Strength | 1 | 2019 | 466 | 0.130 |
Why?
|
Time Factors | 7 | 2016 | 40218 | 0.130 |
Why?
|
Uncertainty | 1 | 2021 | 769 | 0.130 |
Why?
|
Breast Neoplasms | 4 | 2024 | 21206 | 0.130 |
Why?
|
Periodicals as Topic | 1 | 2007 | 1465 | 0.130 |
Why?
|
Transplantation, Homologous | 3 | 2020 | 4833 | 0.130 |
Why?
|
Acute Disease | 2 | 2024 | 7243 | 0.130 |
Why?
|
Cytogenetics | 1 | 2016 | 198 | 0.130 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2016 | 92 | 0.130 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1179 | 0.120 |
Why?
|
Neutrophils | 2 | 2024 | 3786 | 0.120 |
Why?
|
Stem Cell Transplantation | 2 | 2013 | 1596 | 0.120 |
Why?
|
Azacitidine | 1 | 2016 | 336 | 0.120 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2016 | 345 | 0.120 |
Why?
|
Diagnostic Self Evaluation | 1 | 2016 | 228 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1793 | 0.110 |
Why?
|
Vitamin K | 1 | 2016 | 314 | 0.110 |
Why?
|
Minority Groups | 1 | 2021 | 1216 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20760 | 0.110 |
Why?
|
Patient Care Planning | 1 | 2019 | 905 | 0.110 |
Why?
|
Public Opinion | 1 | 2018 | 486 | 0.110 |
Why?
|
Graft vs Host Disease | 2 | 2018 | 3049 | 0.110 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2014 | 96 | 0.110 |
Why?
|
Sulfonamides | 1 | 2023 | 1982 | 0.110 |
Why?
|
Communicable Disease Control | 1 | 2020 | 857 | 0.110 |
Why?
|
Gait | 1 | 2019 | 823 | 0.110 |
Why?
|
Economics | 1 | 2014 | 141 | 0.110 |
Why?
|
Morbidity | 1 | 2019 | 1755 | 0.110 |
Why?
|
Critical Illness | 2 | 2017 | 2756 | 0.110 |
Why?
|
Smoking Cessation | 1 | 2005 | 2085 | 0.110 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3415 | 0.110 |
Why?
|
Reference Values | 1 | 2020 | 4938 | 0.100 |
Why?
|
Patient Care | 1 | 2018 | 629 | 0.100 |
Why?
|
Data Collection | 3 | 2023 | 3327 | 0.100 |
Why?
|
Hodgkin Disease | 2 | 2011 | 1384 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2016 | 646 | 0.100 |
Why?
|
Focus Groups | 2 | 2020 | 1460 | 0.100 |
Why?
|
Follow-Up Studies | 8 | 2019 | 39348 | 0.100 |
Why?
|
Sex Factors | 2 | 2016 | 10632 | 0.100 |
Why?
|
Primary Health Care | 1 | 2008 | 4746 | 0.090 |
Why?
|
Lymphoma, T-Cell | 1 | 2014 | 308 | 0.090 |
Why?
|
Melphalan | 1 | 2013 | 421 | 0.090 |
Why?
|
Memory, Short-Term | 1 | 2018 | 1008 | 0.090 |
Why?
|
Pilot Projects | 2 | 2023 | 8741 | 0.090 |
Why?
|
Affect | 1 | 2019 | 1495 | 0.090 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2019 | 951 | 0.090 |
Why?
|
Sweating | 1 | 2012 | 155 | 0.090 |
Why?
|
Benzamides | 2 | 2013 | 1379 | 0.090 |
Why?
|
Blood Cell Count | 1 | 2012 | 406 | 0.090 |
Why?
|
Leukocyte Count | 2 | 2024 | 1609 | 0.090 |
Why?
|
Sampling Studies | 1 | 2012 | 615 | 0.090 |
Why?
|
Caregivers | 3 | 2023 | 2302 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 1667 | 0.090 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 319 | 0.090 |
Why?
|
Income | 2 | 2016 | 1878 | 0.090 |
Why?
|
Drug Evaluation | 1 | 2011 | 642 | 0.090 |
Why?
|
Injections, Intravenous | 1 | 2012 | 1377 | 0.090 |
Why?
|
Cost Sharing | 1 | 2013 | 409 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1141 | 0.090 |
Why?
|
Inappropriate Prescribing | 1 | 2012 | 212 | 0.090 |
Why?
|
Professional Practice | 1 | 2012 | 314 | 0.080 |
Why?
|
Sunlight | 1 | 2011 | 337 | 0.080 |
Why?
|
Fatigue | 1 | 2017 | 1557 | 0.080 |
Why?
|
Classification | 1 | 2010 | 128 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1061 | 0.080 |
Why?
|
Regression Analysis | 1 | 2019 | 6340 | 0.080 |
Why?
|
Drug Information Services | 1 | 2009 | 51 | 0.080 |
Why?
|
Hematopoietic Stem Cells | 1 | 2022 | 3409 | 0.080 |
Why?
|
Insurance Coverage | 2 | 2018 | 1946 | 0.080 |
Why?
|
Health Personnel | 1 | 2023 | 3385 | 0.080 |
Why?
|
Recurrence | 2 | 2012 | 8509 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1365 | 0.080 |
Why?
|
Databases as Topic | 1 | 2010 | 472 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2017 | 6229 | 0.080 |
Why?
|
Renal Dialysis | 1 | 2018 | 1791 | 0.080 |
Why?
|
Medicaid | 2 | 2013 | 2840 | 0.080 |
Why?
|
Developing Countries | 1 | 2021 | 2910 | 0.080 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2016 | 997 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4860 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1135 | 0.070 |
Why?
|
Intubation, Intratracheal | 1 | 2016 | 1359 | 0.070 |
Why?
|
Health Status Indicators | 1 | 2013 | 969 | 0.070 |
Why?
|
Cytarabine | 2 | 2021 | 695 | 0.070 |
Why?
|
Motivation | 1 | 2018 | 2020 | 0.070 |
Why?
|
Psycholinguistics | 1 | 2008 | 81 | 0.070 |
Why?
|
Watchful Waiting | 1 | 2012 | 492 | 0.070 |
Why?
|
Depression | 3 | 2023 | 8230 | 0.070 |
Why?
|
Anticoagulants | 2 | 2016 | 4852 | 0.070 |
Why?
|
Patient Transfer | 1 | 2014 | 792 | 0.070 |
Why?
|
Veterans | 1 | 2021 | 2669 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 1078 | 0.070 |
Why?
|
Iron | 1 | 2016 | 1813 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1883 | 0.070 |
Why?
|
International Cooperation | 1 | 2013 | 1436 | 0.070 |
Why?
|
Education, Medical | 1 | 2018 | 1742 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2013 | 1273 | 0.070 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9615 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1627 | 0.070 |
Why?
|
Mass Media | 1 | 2009 | 303 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1444 | 0.070 |
Why?
|
Ultraviolet Rays | 1 | 2011 | 1103 | 0.070 |
Why?
|
Piperazines | 2 | 2013 | 2554 | 0.070 |
Why?
|
Pathology, Clinical | 1 | 2010 | 375 | 0.070 |
Why?
|
Young Adult | 6 | 2019 | 60066 | 0.060 |
Why?
|
Drug Costs | 1 | 2013 | 1195 | 0.060 |
Why?
|
International Agencies | 2 | 2017 | 244 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5349 | 0.060 |
Why?
|
Poverty | 2 | 2014 | 2720 | 0.060 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2012 | 1126 | 0.060 |
Why?
|
Pyrimidines | 2 | 2013 | 3048 | 0.060 |
Why?
|
Patient Care Team | 1 | 2016 | 2523 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2013 | 2433 | 0.060 |
Why?
|
Duffy Blood-Group System | 1 | 2024 | 61 | 0.060 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2055 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2014 | 5902 | 0.060 |
Why?
|
World Health Organization | 1 | 2010 | 1329 | 0.050 |
Why?
|
Hospitals, General | 1 | 2008 | 809 | 0.050 |
Why?
|
Mental Disorders | 1 | 2023 | 6874 | 0.050 |
Why?
|
Biomedical Research | 1 | 2019 | 3463 | 0.050 |
Why?
|
Cognition | 1 | 2021 | 7073 | 0.050 |
Why?
|
Vitamins | 1 | 2011 | 1638 | 0.050 |
Why?
|
Health Status | 1 | 2016 | 4091 | 0.050 |
Why?
|
Aging | 2 | 2022 | 8744 | 0.050 |
Why?
|
Patient Satisfaction | 2 | 2019 | 3488 | 0.050 |
Why?
|
Ontario | 1 | 2023 | 403 | 0.050 |
Why?
|
DNA Methylation | 1 | 2016 | 4428 | 0.050 |
Why?
|
Anxiety | 3 | 2023 | 4672 | 0.050 |
Why?
|
Registries | 4 | 2013 | 8375 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5367 | 0.050 |
Why?
|
Endoscopy | 1 | 2012 | 1854 | 0.050 |
Why?
|
Mammaplasty | 2 | 2024 | 1268 | 0.050 |
Why?
|
Medication Adherence | 1 | 2013 | 2187 | 0.050 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 355 | 0.050 |
Why?
|
Critical Care | 1 | 2014 | 2715 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2019 | 14783 | 0.050 |
Why?
|
Eligibility Determination | 1 | 2024 | 421 | 0.040 |
Why?
|
Breast Implants | 1 | 2024 | 414 | 0.040 |
Why?
|
Technology | 1 | 2023 | 296 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2008 | 1542 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 2 | 2013 | 5703 | 0.040 |
Why?
|
Weight Loss | 1 | 2012 | 2721 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 13014 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8748 | 0.040 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2022 | 221 | 0.040 |
Why?
|
Boston | 2 | 2019 | 9374 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2016 | 20227 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 4120 | 0.040 |
Why?
|
Secondary Prevention | 1 | 2005 | 1474 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4598 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5341 | 0.040 |
Why?
|
Vitamin D | 1 | 2011 | 3311 | 0.040 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2019 | 325 | 0.040 |
Why?
|
Adolescent | 5 | 2023 | 89169 | 0.040 |
Why?
|
Anthracyclines | 1 | 2019 | 286 | 0.030 |
Why?
|
Breast Implantation | 1 | 2019 | 225 | 0.030 |
Why?
|
Dexamethasone | 1 | 2023 | 1965 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2006 | 2784 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 9419 | 0.030 |
Why?
|
North America | 1 | 2018 | 1289 | 0.030 |
Why?
|
Enteropathy-Associated T-Cell Lymphoma | 1 | 2014 | 13 | 0.030 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2014 | 40 | 0.030 |
Why?
|
Body Mass Index | 2 | 2016 | 13053 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 162 | 0.030 |
Why?
|
Algorithms | 1 | 2014 | 14164 | 0.030 |
Why?
|
Markov Chains | 1 | 2016 | 979 | 0.030 |
Why?
|
Bone Marrow | 1 | 2023 | 2935 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2024 | 2982 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2002 | 2709 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 2014 | 234 | 0.030 |
Why?
|
Anemia, Aplastic | 1 | 2014 | 231 | 0.030 |
Why?
|
Quality Improvement | 2 | 2019 | 3857 | 0.030 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 168 | 0.020 |
Why?
|
Educational Status | 1 | 2019 | 2515 | 0.020 |
Why?
|
Health Services Research | 1 | 2019 | 1815 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4528 | 0.020 |
Why?
|
New England | 1 | 2014 | 1058 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2005 | 12465 | 0.020 |
Why?
|
Teaching | 1 | 2018 | 1171 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2022 | 2748 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2018 | 1226 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 1741 | 0.020 |
Why?
|
Social Support | 1 | 2019 | 2193 | 0.020 |
Why?
|
Gene Expression | 1 | 2022 | 7598 | 0.020 |
Why?
|
Life Expectancy | 1 | 2016 | 1248 | 0.020 |
Why?
|
Insurance | 1 | 2011 | 115 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1864 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2019 | 2663 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3706 | 0.020 |
Why?
|
New York | 1 | 2011 | 882 | 0.020 |
Why?
|
Program Development | 1 | 2013 | 1300 | 0.020 |
Why?
|
California | 1 | 2011 | 1438 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2013 | 2741 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8542 | 0.020 |
Why?
|
Bone Diseases | 1 | 2009 | 416 | 0.020 |
Why?
|
Students, Medical | 1 | 2018 | 1964 | 0.020 |
Why?
|
Back Pain | 1 | 2009 | 548 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2022 | 10266 | 0.010 |
Why?
|
Decision Making | 1 | 2018 | 3953 | 0.010 |
Why?
|
Cost of Illness | 1 | 2014 | 1951 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2846 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5536 | 0.010 |
Why?
|
Chronic Disease | 1 | 2018 | 9384 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2013 | 2118 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 6211 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6847 | 0.010 |
Why?
|
Observer Variation | 1 | 2008 | 2622 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10873 | 0.010 |
Why?
|
Nurses | 1 | 2011 | 2501 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11095 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21538 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2011 | 1885 | 0.010 |
Why?
|
Dietary Supplements | 1 | 2011 | 3445 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2009 | 2100 | 0.010 |
Why?
|
Diet | 1 | 2011 | 8089 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 15454 | 0.010 |
Why?
|
Child, Preschool | 1 | 2014 | 42669 | 0.010 |
Why?
|
Child | 1 | 2014 | 80917 | 0.000 |
Why?
|